+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

SARS CoV-2 (COVID-19) PCR Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 Market Impact)

  • PDF Icon


  • February 2021
  • Region: Global
  • GlobalData
  • ID: 5232205
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

SARS CoV-2 (COVID-19) PCR Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 market impact) is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.

Severe Acute Respiratory Syndrome Coronavirus, SARS‐CoV‐2, a novel coronavirus from the same family as SARS‐CoV and Middle East respiratory syndrome coronavirus, has spread worldwide leading the World Health Organization (WHO) to declare a pandemic. The disease caused by SARS‐CoV‐2, coronavirus disease 2019 (COVID‐19), presents flu‐like symptoms which can become serious in high‐risk individuals, is a rapidly evolving situation across the globe, and has impacted the vast majority of the world’s population.

To diagnose an individual with COVID-19, a nucleic acid amplification test (NAAT) is used to detect if viral genetic material is present in the patient’s sample. The three most common NAATs used are a) standard, single-use NAATs, b) point-of-care (POC) NAATs, and c) multiplex NAATs, which are also referred to as syndromic NAATs or respiratory panels.

Each of the covered 39 country’s color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.

Key Inclusions of the market model are -

Currently marketed SARS CoV-2 (COVID-19) PCR Tests and evolving competitive landscape -
  • Insightful review of the key industry trends.
  • Annualized total SARS CoV-2 (COVID-19) PCR Tests market revenue by segment and market outlooks from 2015-2030.
  • Granular data on total procedures, units, average selling prices and market values by segment.

Global, Regional and Country level market specific insights -
  • Qualitative market specific information is available with global trends further broken down into regional trends. In addition, analysts provide unique country specific insights on the market.
  • SWOT analysis for SARS CoV-2 (COVID-19) PCR Tests market.
  • Competitive dynamics insights and trends provided for SARS CoV-2 (COVID-19) PCR Tests market.

Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.
  • Country specific overview of the healthcare system.
  • Country specific reimbursement policies.
  • Country specific medtech regulatory landscape.

Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies covered - F. Hoffmann-La Roche Ltd, Abbott Laboratories, Danaher Corp,Hologic Inc, bioMérieux SA, and Others

Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina and Chile.


This Market Model gives important, expert insight you won’t find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -
  • CMO executives who must have deep understanding of the SARS CoV-2 (COVID-19) PCR Tests market place to make strategic planning and investment decisions.
  • Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
  • Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to Buy

The model will enable you to -
  • Understand the impact of COVID-19 on SARS CoV-2 (COVID-19) PCR Tests market.
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving SARS CoV-2 (COVID-19) PCR Tests market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the SARS CoV-2 (COVID-19) PCR Tests market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the company share of market leaders.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track device sales in the global and country-specific SARS CoV-2 (COVID-19) PCR Tests market from 2015-2030.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • F. Hoffmann-La Roche Ltd
  • Abbott Laboratories
  • Danaher Corp
  • Hologic Inc
  • bioMérieux SA